刘锋;师秀雪;

• 1:郑州大学第一附属医院

摘要(Abstract)：

目的探讨阿尔茨海默病(AD)患者精神行为症状与动脉粥样硬化的关系。方法选取2019-06—2020-03郑州大学第一附属医院收治的AD患者51例,根据颈部血管超声检查结果分为无IMT增厚或斑块组、IMT增厚或斑块组;根据经颅多普勒超声检查结果将IMT增厚或斑块组进一步分为脑动脉硬化组、无脑动脉硬化组,测定患者血浆同型半胱氨酸(Hcy)水平、简易精神状态量表评分,并进行对比分析。结果 IMT增厚或斑块组血浆Hcy水平显著高于无IMT增厚或斑块组(P<0.05);简易精神状况评分比较,IMT增厚或斑块组显著低于无IMT增厚或斑块组(P<0.001)。IMT增厚或斑块组中脑动脉硬化组血浆Hcy水平显著高于无脑动脉硬化组(P<0.001),简易精神状况评分显著低于无脑动脉硬化组(P<0.001)。结论 AD患者动脉粥样硬化程度越重,Hcy水平可能越高,且其精神行为症状可能越重。

关键词(KeyWords)： 阿尔茨海默病;颈动脉粥样硬化;精神行为;同型半胱氨酸;颈动脉斑块;颅多普勒超声;脑动脉硬化

Abstract:

Keywords:

基金项目(Foundation): 河南省科技厅社会发展攻关项目(编号:172102310048)

作者(Authors): 刘锋;师秀雪;

参考文献(References)：

• [1] WORTMANN M.World Alzheimer report 2014:Dementia and risk reduction[J].Alzheimer’s Dement,2015,7(11):837.
• [2] 井初雅,井长信,方杰,等.神经免疫在阿尔茨海默病中的作用研究进展[J].中国实用神经疾病杂志,2019,22(3):330-336.DOI:10.12083/SYSJ.2019.03.060.
• [3] MCKHANN G,DRACHMAN D,FOLSTEIN M,et al.Clinical diagnosis of Alzheimer’s disease:report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease[J].Neurology,1984,34(7):939-944.
• [4] LIU L,CHAN C.The role of inflammasome in Alzheimer's disease[J].Ageing Res Rev,2014,15:6-15.DOI:10.1016/j.arr.2013.12.007.
• [5] WHITE C S,LAWRENCE C B,BROUGH D,et al.Inflammasomes as therapeutic targets for Alzheimer's disease[J].Brain Pathol,2017,27(2):223-234.DOI:10.1111/bpa.12478.
• [6] YAP J K Y,PICKARD B S,CHAN E W L,et al.The Role of Neuronal NLRP1 Inflammasome in Alzheimer's Disease:Bringing Neurons into the Neuroinflammation Game[J].Mol Neurobiol,2019,56(11):7741-7753.DOI:10.1007/s12035-019-1638-7.
• [7] HELVIK A S,SELB?K G,?ALTYTé BENTH J,et al.The course of neuropsychiatric symptoms in nursing home residents from admission to 30-month follow-up[J].PLoS One,2018,13(10):e206147.DOI:10.1371/journal.pone.0206147.
• [8] LIU L,CHAN C.IPAF inflammasome is involved in interleukin-1β production from astrocytes,induced by palmitate;implications for Alzheimer's Disease[J].Neurobiol Aging,2014,35(2):309-321.DOI:10.1016/j.neurobiolaging.2013.08.016.
• [9] HUANG Y M L,MUCKE L.Alzheimer Mechanisms and Therapeutic Strategies[J].Cell,2012,148(6):1204-1222.DOI:10.1016/j.cell.2012.02.040.
• [10] XIANG J.Carotid atherosclerosis promotes the progression of Alzheimer's disease:A three-year prospective study[J].Exp Ther Med,2017,14(2):1321-1326.DOI:10.3892/etm.2017.4661.
• [11] GUPTA A,IADECOLA C.Impaired Aβ clearance:a potential link between atherosclerosis and Alzheimer's disease[J].Front Aging Neurosci,2015,7:115.DOI:10.3389/fnagi.2015.00115.
• [12] QIAO J,LU W,WANG J,et al.Vascular Risk Factors Aggravate the Progression of Alzheimer's Disease:A 3-Year Follow-Up Study of Chinese Population[J].Am J Alzheimers Dis Other Demen,2014,29(6):521-525.DOI:10.1177/1533317514522853.
• [13] LóPEZ-OLóRIZ J,LóPEZ-CANCIO E,ARENILLAS J F,et al.Asymptomatic cervicocerebral atherosclerosis,intracranial vascular resistance and cognition:The AsIA-Neuropsychology Study[J].Atherosclerosis,2013,230(2):330-335.DOI:10.1016/j.atherosclerosis.2013.08.011.
• [14] JOHNSEN S H,MATHIESEN E B.Carotid plaque compared with intima-media thickness as a predictor of coronary and cerebrovascular disease[J].Curr Cardiol Rep,2009,11(1):21-27.DOI:10.1007/s11886-009-0004-1.
• [15] MOREIRA S C,JANSEN A K,SILVA F M.Dietary interventions and cognition of Alzheimer's disease patients:a systematic review of randomized controlled trial[J].Dement Neuropsychol,2020,14(3):258-282.DOI:10.1590/1980-57642020dn14-030008.
• [16] NAJM R,ZALOCUSKY KA,ZILBERTER M,et al.In Vivo Chimeric Alzheimer's Disease Modeling of Apolipoprotein E4 Toxicity in Human Neurons[J].Cell Rep,2020,32(4):107962.DOI:10.1016/j.celrep.2020.107962.
• [17] 周雪莹,徐武华.脑内淋巴引流和Aβ清除机制对阿尔茨海默病防治的研究进展[J].中国实用神经疾病杂志,2020,23(9):822-825.DOI:10.12083/SYSJ.2020.09.132.
• [18] Alzheimer's Association.2016 Alzheimer's disease facts and figures[J].Alzheimers Dement,2016,12(4):459-509.DOI:10.1016/j.jalz.2016.03.001.
• [19] CALSOLARO V,EDISON P.Neuroinflammation in Alzheimer's disease:Current evidence and future directions[J].Alzheimers Dement,2016,12(6):719-732.DOI:10.1016/j.jalz.2016.02.010.
• [20] KARLAWISH J,JACK C R JR,ROCCA W A,et al.Alzheimer's disease:The next frontier-Special Report 2017[J].Alzheimers Dement,2017,13(4):374-380.DOI:10.1016/j.jalz.2017.02.006.
• [21] PETER-DEREX L,YAMMINE P,BASTUJI H,et al.Sleep and Alzheimer's disease[J].Sleep Med Rev,2015,19:29-38.DOI:10.1016/j.smrv.2014.03.007.
• [22] MCKHANN G M,KNOPMAN D S,CHERTKOW H,et al.The diagnosis of dementia due to Alzheimer's disease:recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease[J].Alzheimers Dement,2011,7(3):263-269.DOI:10.1016/j.jalz.2011.03.005.
• [23] NEBEL R A,AGGARWAL N T,BARNES L L,et al.Understanding the impact of sex and gender in Alzheimer's disease:A call to action[J].Alzheimers Dement,2018,14(9):1171-1183.DOI:10.1016/j.jalz.2018.04.008.
• [24] QIU C,KIVIPELTO M,VON STRAUSS E.Epidemiology of Alzheimer's disease:occurrence,determinants,and strategies toward intervention[J].Dialogues Clin Neurosci,2009,11(2):111-128.
• [25] MIELKE M M,FERRETTI M T,IULITA M F,et al.Sex and gender in Alzheimer's disease-Does it matter?[J].Alzheimers Dement,2018,14(9):1101-1103.DOI:10.1016/j.jalz.2018.08.003.
• [26] MATTHEWS K A,XU W,GAGLIOTI A H,et al.Racial and ethnic estimates of Alzheimer's disease and related dementias in the United States (2015-2060) in adults aged ≥65 years[J].Alzheimers Dement,2019,15(1):17-24.DOI:10.1016/j.jalz.2018.06.3063.
• [27] ISAACSON R S,GANZER C A,HRISTOV H,et al.The clinical practice of risk reduction for Alzheimer's disease:A precision medicine approach[J].Alzheimers Dement,2018,14(12):1663-1673.DOI:10.1016/j.jalz.2018.08.004.
• [28] KNOPMAN D S,HAEBERLEIN S B,CARRILLO M C,et al.The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease:Perspectives from the Research Roundtable[J].Alzheimers Dement,2018,14(4):563-575.DOI:10.1016/j.jalz.2018.03.002.
• [29] TAKOUSIS P,SADLON A,SCHULZ J,et al.Differential expression of microRNAs in Alzheimer's disease brain,blood,and cerebrospinal fluid[J].Alzheimers Dement,2019,15(11):1468-1477.DOI:10.1016/j.jalz.2019.06.4952.
• [30] SHAW L M,ARIAS J,BLENNOW K,et al.Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease[J].Alzheimers Dement,2018,14(11):1505-1521.DOI:10.1016/j.jalz.2018.07.220.
• [31] 郑伟,林敬源,林小娟.阿尔茨海默病早期快速筛查的简易风险评估模型探索[J].中国实用神经疾病杂志,2019,22(18):1981-1987.DOI:10.12083/SYSJ.2019.18.331.
• [32] LIU X,HOU D,LIN F,et al.The role of neurovascular unit damage in the occurrence and development of Alzheimer's disease[J].Rev Neurosci,2019,30(5):477-484.DOI:10.1515/revneuro-2018-0056.
• [33] 袁树华,崔传举,李艾帆.阿尔茨海默病与脑白质疏松血浆同型半胱氨酸水平的相关性研究[J].中国实用神经疾病杂志,2019,22(1):56-59.DOI:10.12083/SYSJ.2019.01.011.
• [34] RUTHIRAKUHAN M,LANCT?T K L,DI SCIPIO M,et al.Biomarkers of agitation and aggression in Alzheimer's disease:A systematic review[J].Alzheimers Dement,2018,14(10):1344-1376.DOI:10.1016/j.jalz.2018.04.013.
• [35] MORTAMAIS M,ASH J A,HARRISON J,et al.Detecting cognitive changes in preclinical Alzheimer's disease:A review of its feasibility[J].Alzheimers Dement,2017,13(4):468-492.DOI:10.1016/j.jalz.2016.06.2365.
• [36] MCRAE-MCKEE K,UDEH-MOMOH C T,PRICE G,et al.Perspective:Clinical relevance of the dichotomous classification of Alzheimer's disease biomarkers:Should there be a "gray zone" [J].Alzheimers Dement,2019,15(10):1348-1356.DOI:10.1016/j.jalz.2019.07.010.
• [37] GUNN-MOORE D,KAIDANOVICH-BEILIN O,GALLEGO IRADI M C,et al.Alzheimer's disease in humans and other animals:A consequence of postreproductive life span and longevity rather than aging[J].Alzheimers Dement,2018,14(2):195-204.DOI:10.1016/j.jalz.2017.08.014.